ArticleTurkish journal of pharmaceutical sciences2025
Investigation of the Effects of Polyunsaturated Fatty Acid Ratios in Human SH-SY5Y Cells by
Article in Turkish journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Neuroblastoma, an embryonic tumor of the sympathetic nervous system, is the deadliest type of cancer, accounting for 6-9% of all childhood cancers. The omega (ω)-6 [linoleic acid (LA)]: ω-3 [eicosapentaenoic acid (EPA)]=13/1 ratio is associated with the presence of chronic disease, and it has been reported that reducing this ratio to 7/1 protects against cancer and cardiovascular diseases. This study aimed to investigate the anticancer effects of different ratios of ω-3 and ω-6 fatty acids in human neuroblastoma cells (SHSY-5Y). Materials and Methods: SHSY-5Y cells were treated with different ratios of ω-3 and ω-6 fatty acids for 48 and 72 h. The viability of ω-3 and ω-6 fatty acid-treated cells was measured using the methylthiazolyldiphenyl-tetrazolium bromide. The percentage of cell apoptosis was detected using the Fluorescein Isothiocyanate-conjugated Annexin-V/PI assay, and reactive oxygen species (ROS) analysis was performed using flow cytometry. The expression levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and Results: EPA and LA separately significantly inhibited the proliferation of SH-SY5Y cells within 48 h (p<0.001). It was found that apoptosis decreased significantly in all groups due to the application of polyunsaturated fatty acids at different ratios, and the most effective dose was ω-3:ω-6 ratio: 1/1. ROS levels were significantly decreased compared with the control group and the lowest ROS level was observed in the ω-3:ω-6 ratio: 1/4 group. Both TNF-α, IL-6, and TGFβ1 mRNA expressions increased significantly after the addition of fatty acid mixtures compared with the control; they were observed to decrease with an increasing ω-6 ratio. Conclusion: This study is the first to examine the effects of the ω-3:ω-6 ratio on neuroblastoma cancer cells. The application of ω fatty acids decreased apoptosis at all ratios. In contrast, when the ω-3: ω-6 ratio increased, the amount of ROS. Additionally, as the ω-3:ω-6 ratio increases, a decrease in the release of pro-inflammatory cytokines is noted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.